BOLD - Audentes Therapeutics, Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Show:
Income Statement
Balance Sheet
Cash Flow

Income Statement

Annual
All numbers in thousands
Revenue12/31/201812/31/201712/31/201612/31/2015
Total Revenue----
Cost of Revenue----
Gross Profit----
Operating Expenses
Research Development104,37075,63948,66820,104
Selling General and Administrative30,00217,27511,2766,091
Non Recurring----
Others----
Total Operating Expenses134,37292,91459,94426,195
Operating Income or Loss-134,372-92,914-59,944-26,195
Income from Continuing Operations
Total Other Income/Expenses Net5,551430276-263
Earnings Before Interest and Taxes-134,372-92,914-59,944-26,195
Interest Expense----
Income Before Tax-128,821-92,484-59,668-26,458
Income Tax Expense--2,246--
Minority Interest----
Net Income From Continuing Ops-128,821-90,238-59,668-26,458
Non-recurring Events
Discontinued Operations----
Extraordinary Items----
Effect Of Accounting Changes----
Other Items----
Net Income
Net Income-128,821-90,238-59,668-26,458
Preferred Stock And Other Adjustments----
Net Income Applicable To Common Shares-128,821-90,238-59,668-26,458